Akeso Inc
HKEX:9926

Watchlist Manager
Akeso Inc Logo
Akeso Inc
HKEX:9926
Watchlist
Price: 59.9 HKD -1.56% Market Closed
Market Cap: 53.8B HKD
Have any thoughts about
Akeso Inc?
Write Note

Akeso Inc
Other Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Akeso Inc
Other Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Akeso Inc
HKEX:9926
Other Liabilities
ÂĄ159.6m
CAGR 3-Years
44%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Other Liabilities
ÂĄ1.6B
CAGR 3-Years
-18%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Other Liabilities
ÂĄ1.4B
CAGR 3-Years
19%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Other Liabilities
ÂĄ33.6m
CAGR 3-Years
-29%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Other Liabilities
ÂĄ215.4m
CAGR 3-Years
-4%
CAGR 5-Years
19%
CAGR 10-Years
13%
Imeik Technology Development Co Ltd
SZSE:300896
Other Liabilities
ÂĄ3.4m
CAGR 3-Years
-30%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
No Stocks Found

Akeso Inc
Glance View

Market Cap
51.9B HKD
Industry
Biotechnology

In the bustling landscape of biotechnology, Akeso Inc. emerges as a dynamic force addressing the dynamic and often daunting challenges of the medical world. Founded in 2012 and headquartered in China, this innovative company has made significant strides in the realm of biopharmaceuticals, particularly focusing on the research and development of novel therapies for oncology and immunology. Akeso Inc. differentiates itself through its comprehensive end-to-end approach, spanning discovery, clinical development, and commercialization. By leveraging its robust pipeline of therapeutic antibodies, the company constantly seeks to pioneer breakthroughs in cancer treatment and autoimmune disorders, thus driving its mission to enhance patient outcomes and address unmet medical needs. The economic engine of Akeso Inc. is driven by its ability to transform scientific research into viable therapeutic products. Revenue generation centers around the commercialization of their proprietary drugs, which often involves collaborations and strategic partnerships with major pharmaceutical players globally. These alliances not only expand the reach of Akeso's innovations but also provide essential capital and shared expertise that accelerate product advancement. The company's business model is further bolstered by licensing agreements and milestone payments, creating a steady stream of income as they navigate the rigorous pathways of drug approval and market entry. Through these ventures, Akeso Inc. not only secures its financial health but also continuously reinvests in its research endeavors, fueling a cycle of innovation that propels it forward in the competitive biotech arena.

Intrinsic Value
59.24 HKD
Overvaluation 1%
Intrinsic Value
Price

See Also

What is Akeso Inc's Other Liabilities?
Other Liabilities
159.6m CNY

Based on the financial report for Dec 31, 2023, Akeso Inc's Other Liabilities amounts to 159.6m CNY.

What is Akeso Inc's Other Liabilities growth rate?
Other Liabilities CAGR 5Y
32%

Over the last year, the Other Liabilities growth was 0%. The average annual Other Liabilities growth rates for Akeso Inc have been 44% over the past three years , 32% over the past five years .

Back to Top